Patents by Inventor Ralph Grosswald

Ralph Grosswald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of reducing pulmonary exacerbations in respiratory disease patients
    Patent number: 11890282
    Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: February 6, 2024
    Assignee: Celltaxis, LLC
    Inventors: Sanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman
  • METHOD OF REDUCING ABERRANT IMMUNE RESPONSE OR RISK OF PROGRESSION IN COVID-19
    Publication number: 20220288034
    Abstract: The invention is directed to methods of treating a patient that is or has been infected with COVID-19 comprising the use of acebilustat. The methods include reducing the risk of COVID-19 progression, reducing or preventing aberrant immune response, reducing or preventing COVID-19 mediated lung injury, and/or treating late sequelae of COVID-19.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 15, 2022
    Inventors: Eric B. Springman, Ralph Grosswald, Sanjeev Ahuja
  • METHOD OF REDUCING PULMONARY EXACERBATIONS IN RESPIRATORY DISEASE PATIENTS
    Publication number: 20210236484
    Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
    Type: Application
    Filed: January 11, 2021
    Publication date: August 5, 2021
    Inventors: Sanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman
  • Methods of inhibiting leukotriene A4 hydrolase
    Patent number: 10898471
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 26, 2021
    Assignee: CELLTAXIS, LLC
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Method of reducing pulmonary exacerbations in respiratory disease patients
    Patent number: 10898484
    Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: January 26, 2021
    Assignee: CELLTAXIS, LLC
    Inventors: Sanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman
  • METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE
    Publication number: 20200138791
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Application
    Filed: June 17, 2019
    Publication date: May 7, 2020
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • METHOD OF REDUCING PULMONARY EXACERBATIONS IN RESPIRATORY DISEASE PATIENTS
    Publication number: 20190365750
    Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 5, 2019
    Inventors: Sanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman
  • Methods of inhibiting leukotriene A4 hydrolase
    Patent number: 10350197
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 16, 2019
    Assignee: Celtaxsys, Inc.
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE
    Publication number: 20180117014
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Application
    Filed: November 2, 2017
    Publication date: May 3, 2018
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Methods of inhibiting leukotriene A4 hydrolase
    Patent number: 9820974
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 21, 2017
    Assignee: Celtaxsys, Inc.
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE
    Publication number: 20160067226
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 10, 2016
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald